Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Brunei Darussalam is experiencing steady growth in recent years.
Customer preferences: Immunosuppressants are primarily used to prevent organ rejection after a transplant. As the demand for organ transplants increases globally, the demand for immunosuppressants also increases. In Brunei Darussalam, the majority of the population is Muslim, and organ donation is not widely accepted due to religious beliefs. Therefore, the demand for immunosuppressants in the country is primarily driven by the need for treatment of autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis.
Trends in the market: The market for immunosuppressants in Brunei Darussalam is primarily driven by the demand for branded drugs. The majority of the population can afford the high cost of branded drugs due to the country's high GDP per capita. However, the government is taking steps to increase the availability of generic drugs to reduce healthcare costs. As a result, the market for generic immunosuppressants is expected to grow in the coming years.
Local special circumstances: Brunei Darussalam is a small country with a population of just over 400,000 people. The healthcare system is primarily funded by the government, and healthcare services are provided free of charge to citizens and permanent residents. The government is committed to providing high-quality healthcare services to its citizens and has invested heavily in the healthcare sector in recent years. As a result, the demand for immunosuppressants is expected to increase in the coming years, as the government continues to invest in the healthcare sector.
Underlying macroeconomic factors: Brunei Darussalam is a small, wealthy country with a high GDP per capita. The country's economy is heavily dependent on oil and gas exports, which account for over 90% of the country's total exports. The government is taking steps to diversify the economy and reduce its dependence on oil and gas exports. As a result, the government is investing heavily in infrastructure, education, and healthcare, which is expected to drive the growth of the immunosuppressants market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
